Paula Persson

Clinical Pharmacology Specialist
Novo Nordisk A/S

Presentation(s):

• OC 40.1 - FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy

  Monday, July 11, 2022
  2:45 PM – 3:00 PM